The Defense Health Agency awarded Duke University a $402,500 Project Grant under the Military Medical Research and Development program (CFDA 12.420) for the period of June 1, 2023 through May 31, 2025. The grant will support Duke University's research efforts to target the ferropotosis protection mechanism of serum to disable cancer metastasis. The Military Medical Research and Development program aims to transform military and public health through innovative medical research solutions for both...
The Defense Health Agency awarded a $724,500 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Duke University. The grant, titled "Targeting Dormancy-Associated Immune Tolerance to Eliminate Residual Breast Cancer," will fund advanced biomedical research to transform healthcare for military service members, veterans, and the broader public. The research, to be conducted at Duke University's Office of Research Administration Division from March...
The Defense Health Agency awarded Duke University a $1,167,250 Project Grant (CFDA 12.420 - Military Medical Research and Development) with a performance period from June 1, 2024 to May 31, 2027. The grant funding supports Duke's research on the role of the NLRP3-NLRC5 signaling pathway in melanoma immune evasion and dormancy. The research aims to advance the understanding of mechanisms underlying melanoma progression, with the potential to inform new therapeutic approaches. As a prominent...
The U.S. Defense Health Agency awarded a $1,449,000 Project Grant to Duke University to conduct research aimed at "Identifying Essential Molecular Mechanisms for Advanced Prostate Cancer Growth by a New Chemical Compound." This grant is funded under the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420), which supports biomedical research to improve the health and care of military service members, veterans, and their families. The...
The Defense Health Agency awarded Duke University a $3,811,150.00 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to conduct a research project titled "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant period runs from April 1, 2024 to March 31, 2028. The key products and services to be delivered under this award include comprehensive single-cell and spatial analysis of breast cancer samples to characterize tumor heterogeneity...
The Department of Defense's Defense Health Agency awarded a $4,818,759 Project Grant to Duke University under the Military Medical Research and Development program (CFDA 12.420) for the project "SINGLE-CELL AND SPATIAL ANALYSIS OF LETHAL BREAST CANCERS". The grant, awarded on April 1, 2024, will fund research to improve understanding and treatment of lethal breast cancers through advanced single-cell and spatial analysis techniques. This work supports the program's goals of...
The Defense Health Agency awarded Duke University a $804,999 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to support research on "DETECTING MISSED METASTASES FROM NOMINALLY EARLY-STAGE MELANOMAS WITH PUMP-PROBE MICROSCOPY". The award runs from September 1, 2023 to August 31, 2026. The Project Grant enables Duke's research to transform health care for Service Members and the American public through innovative and impactful biomedical research...
The U.S. Department of Defense's Defense Health Agency awarded a $845,250 Project Grant under the Military Medical Research and Development (CFDA 12.420) program to Duke University. The grant, with a performance period from July 1, 2025 to June 30, 2028, will fund research to engineer TCR-T cells to target human endogenous retroviruses for non-small cell lung cancer immunotherapy. The goal of this advanced biomedical research is to transform healthcare for military service members, veterans, and...
The Department of Defense's Defense Health Agency awarded a $700,032 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, effective August 1, 2025 through July 31, 2029, will fund research to investigate "Imaging Strategies and Biomarkers for Detecting the Metabolic Interplay of Glutamine and Aspartate in RCC." This research aims to transform healthcare for military service members, veterans, and the broader public by...
The Department of Defense's Defense Health Agency awarded a $241,500 Project Grant to Duke University under the Military Medical Research and Development (CFDA 12.420) program. The grant, awarded on September 1, 2025, supports research to understand the molecular communication between different types of prostate cancer cells. This fundamental research, to be conducted at Duke University in Durham, North Carolina, aims to transform healthcare for military service members, veterans, and the...